April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Designing and Manufacturing a Refillable Multi-Drug Capsule Ring Platform
Author Affiliations & Notes
  • C. J. Bishop
    Biomedical Engineering,
    University of Utah, Salt Lake City, Utah
  • H. J. Sant
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • S. A. Molokhia
    Ophthalmology, Moran Eye Center, Salt Lake City, Utah
  • R. M. Burr
    Biomedical Engineering,
    University of Utah, Salt Lake City, Utah
  • B. K. Gale
    Mechanical Engineering,
    University of Utah, Salt Lake City, Utah
  • B. K. Ambati
    Ophthalmology, Moran Eye Center, Salt Lake City, Utah
  • Footnotes
    Commercial Relationships  C.J. Bishop, None; H.J. Sant, None; S.A. Molokhia, None; R.M. Burr, None; B.K. Gale, WO 2009140246, P; B.K. Ambati, WO 2009140246, P.
  • Footnotes
    Support  University of Utah TCP, State of Utah Center of Excellence
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5331. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. J. Bishop, H. J. Sant, S. A. Molokhia, R. M. Burr, B. K. Gale, B. K. Ambati; Designing and Manufacturing a Refillable Multi-Drug Capsule Ring Platform. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5331.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : AMD treatment requires monthly intravitreal injections which are uncomfortable, risky, and costly. Because glaucoma is treated using topical polypharmaceutic regimens, patient compliance and drug-target interactions are low. A controlled delivery device would benefit both ocular diseases and transcend the patient interface. Our Capsule Drug Rings (CDR) are implanted in the capsule bag periphery during IOL placement. The CDRs are to be refilled every 6 months to 1 year in situ.

Methods: : CDRs are made of well-established biocompatible materials. The inflatable shell of the CDR is a flexible polycarbonate-based polyether urethane which resists hydrolytic degradation improving longevity in vivo. A CO2 laser was used to laminate the shell edge of the CDR. Refilling Ports were made of polyimide tubing and resealing polydimethylsiloxane plugs acting as a one-way valve. One side of the shell consisted of a 1 mm2 oval window, covered by a 30 nm diameter pore-size polyethersulfone filter. Islets were placed at the ends of the device for surgical manipulation. CDRs were implanted in rabbits during intraocular lens implantation.

Results: : Each port re-seals and holds at least 40 mm Hg up to 30 insertions. The carbothane shell’s inner and outer diameters are 11.0 and 13.0 mm, respectively. The thickness of the shell pre and post-inflation is 200 µm and 750 µm, respectively. The drug reservoir holds 80 µL. Significantly, various sections of the CDR shell were laminated using different laser parameters. The edges with greater curvature required greater speed or less power. Radial lamination (vs horizontal or vertical) due to the symmetry and curvature of the ring device was far superior for proper sealing.

Conclusions: : The CDR multi-drug platform is a promising device for treating multiple diseases simultaneously (AMD, Glaucoma, etc.). The CDR filter placement, thickness, pore size/density, window size, and drug concentration can be altered to optimize near zero order pharmacokinetics for a given drug molecule.

Keywords: drug toxicity/drug effects • age-related macular degeneration • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×